Literature DB >> 25912145

Sirolimus for Retinal Astrocytic Hamartoma Associated with Tuberous Sclerosis Complex.

Zhi-Qiao Zhang1, Cheng Shen2, Qin Long1, Zhi-Kun Yang1, Rong-Ping Dai1, Jun Wang2, Weihong Zhang3, Qingqing Pan4, Zhaohui Zhu4, Kai-Feng Xu5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25912145     DOI： 10.1016/j.ophtha.2015.03.023

Source DB:  PubMed          Journal:  Ophthalmology        ISSN： 0161-6420            Impact factor:   12.079


× No keyword cloud information.
  7 in total

Review 1.  Congenital focal abnormalities of the retina and retinal pigment epithelium.

Authors:  Yingna Liu; Anthony T Moore
Journal:  Eye (Lond)       Date:  2020-05-04       Impact factor: 3.775

2.  Mammalian target of rapamycin inhibitors for the treatment of astrocytic hamartoma in tuberous sclerosis complex (TSC).

Authors:  Ofri Vorobichik Berar; Michal Tzadok; Ofira Zloto; Iris Moroz; Idan Hecht; Anne Ampaire Musika; Omer Shlomovitz; Ido-Didi Fabian; Vicktoria Vishnevskia Dai
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-01       Impact factor: 3.535

3.  Rapid symptomatic and structural improvement of a retinal astrocytic hamartoma in response to anti-VEGF therapy: A case report.

Authors:  Kevin C Allan; Hong-Uyen Hua; Arun D Singh; Alex Yuan
Journal:  Am J Ophthalmol Case Rep       Date:  2022-06-01

Review 4.  [Retinal tumors in adults: Part 2 nonvascular tumors of retina and retinal pigment epithelium].

Authors:  Roya Piria; Felix Rommel; Michael Zimbelmann; Kristina Erikson; Neele Babst; Anton Brosig; Josephine Christin Freitag; Mahdy Ranjbar; Salvatore Grisanti; Vinodh Kakkassery
Journal:  Ophthalmologe       Date:  2021-07-29       Impact factor: 1.059

5.  Subthreshold micropulse laser photocoagulation therapy in a case of bilateral retinal astrocytic hamartomas with tuberous sclerosis complex: A case report.

Authors:  Shenshen Yan; Yanyun Chen; Rui Chen; Bei Tian; Zheqing Li
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

Review 6.  Is mTOR Inhibitor Good Enough for Treatment All Tumors in TSC Patients?

Authors:  Samy L Habib; Noor Y Al-Obaidi; Maciej Nowacki; Katarzyna Pietkun; Barbara Zegarska; Tomasz Kloskowski; Wojciech Zegarski; Tomasz Drewa; Edward A Medina; Zhenze Zhao; Sitai Liang
Journal:  J Cancer       Date:  2016-07-21       Impact factor: 4.207

7.  Hyperactivated mTORC1 downregulation of FOXO3a/PDGFRα/AKT cascade restrains tuberous sclerosis complex-associated tumor development.

Authors:  Li Wang; Zhaofei Ni; Yujie Liu; Shuang Ji; Fuquan Jin; Keguo Jiang; Junfang Ma; Cuiping Ren; Hongbing Zhang; Zhongdong Hu; Xiaojun Zha
Journal:  Oncotarget       Date:  2017-07-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.